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Abstract
Background: During the last few years, the knowledge of drug, disease phenotype and protein has been rapidly
accumulated and more and more scientists have been drawn the attention to inferring drug-disease associations
by computational method. Development of an integrated approach for systematic discovering drug-disease
associations by those informational data is an important issue.
Methods: We combine three different networks of drug, genomic and disease phenotype and assign the weights
to the edges from available experimental data and knowledge. Given a specific disease, we use our network
propagation approach to infer the drug-disease associations.
Results: We apply prostate cancer and colorectal cancer as our test data. We use the manually curated drug-disease
associations from comparative toxicogenomics database to be our benchmark. The ranked results show that our
proposed method obtains higher specificity and sensitivity and clearly outperforms previous methods. Our result also
show that our method with off-targets information gets higher performance than that with only primary drug targets
in both test data.
Conclusions: We clearly demonstrate the feasibility and benefits of using network-based analyses of chemical,
genomic and phenotype data to reveal drug-disease associations. The potential associations inferred by our
method provide new perspectives for toxicogenomics and drug reposition evaluation.
Background
Disease an intricate phenotype is usually caused by conge-
nital disorder or dysfunctions of abnormal genes which
induce multi-factor-driven alterations and disrupt func-
tional modules [1]. Drugs achieve their therapeutic effect
by changing downstream processes of their targets which
contend with the alterations of those abnormal genes.
The previous reports also showed that pharmaceutical
company takes approximately 15 years and over $1 billion
to develop a novel drug into the market and more than
90% of experimental drugs fail to move beyond the early
clinical test stages [2,3]. Because drug discovery is
complexity, time-consuming process and there are odds of
low therapeutic efficacy and/or unacceptable toxicity [4,5].
With the merits of shorting development time and
reducing risk, more and more scientists have been drawn
attention to inferring drug-disease associations by compu-
tational method. Development of an integrated approach
for systematic discovering those associations is necessary.
Several studies investigated some methods to increase
the efficacy of drug discovery and they found there are
positive and negative relationships between existing drugs
and disease phenotypes. The Comparative Toxicoge-
nomics Database (CTD; http://ctd.mdibl.org) is the public
database which inferred chemical-disease associations
by manually curated chemical-gene interactions, and
gene-disease relationships from published literature [6].
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Cheng also presented a comprehensive predicted database
of chemical -gene-disease associations (PredCTD) by
integrating the information from chemical, gene, and
disease [7]. Pharmacogenetics and pharmacogenomics
knowledge base (PharmGKB) is a repository which con-
tains the relationships between genomics, drug-response
and its related phenotype and clinical information [8].
Eichborn developed PROMISCUOUS database which
includes network-based resources of protein-protein and
protein-drug interactions, side-effects and structural
information [9].
The high-throughput microarray technology plays an
important role in investigating drug-disease associations
by providing a genome-side monitoring of gene expres-
sion in the past decade. Some methods aims at restoring
the abnormal state to normal state which means the
expressions of the transcriptional level induced by drug
should reverse those under disease state. On the other
hand, if the differential expression profile under drug
exposure and disease states is significantly anti-correlated,
the drug compounds may have the potential to cure that
disease. The Connectivity Map (Cmap) project is one
of the most comprehensive and systematic approaches
for drug-disease associations [10]. The Cmap provided
a reference collection of genome-wide gene expressions
profiles among drugs, which were obtained by systemati-
cally exposing to few key cell lines [11]. Drug compounds
negatively correlated to disease-specific gene signature
may be the candidate therapeutic for further investigation.
On the other hand, drug compounds positively correlated
to gene signature are able to induce the disease phenotype.
Li built disease-specific drug-protein associations derived
from the Cmap by integrating gene/protein and drug con-
nectivity information based on protein interaction network
(PIN) and literature mining from PubMed abstracts [12].
Previous research used the “guilt by association” (GBA)
approach, which assumed that when two diseases share
similar therapies then the drug treats only one of the two
might be also treat another, to predict novel drug-disease
associations [13]. With a gold standard set of the drug-
disease associations, Gottlieb designed a novel computa-
tional method called PREDICT to identify drug-disease
associations and also predict new drug indications based
on their features including chemical structure, side
effects, gene expression profile, and chemical-protein
interactome [14]. However, to build an accurate predic-
tion model based on different feature must have the
positive and negative data to infer drug-disease associa-
tions. There are some technically difficulties to obtain
negative data such as non-drug targets due to the lack
of value of research. Except learning a classifier to predict
the associations between drugs and disease, network-
based approach has been widely used to infer the relation-
ships. In genetic and molecular biology, increasing
evidences suggested that common functional modules
are not affected by an individual gene but usually are
organized by a group of interacting genes underlie similar
diseases, which point out the therapeutic importance of
those modules [15]. Therefore, the other basic hypothesis
is that the mechanism of the drug and disease in
the pathological processes may share similar functional
modules. Daminelli created a drug-target-disease network
and mined the bi-cliques where every drug is linked to
every target and disease [16]. If the known data form
an incomplete bi-clique, the incomplete relations in the
bi-cliques to be identified as predicted links between drugs
and diseases. Ye integrated known drug target information
and proposed a disease-oriented strategy for evaluating the
relationships between drugs and a specific disease based
on their pathway profile [17].
The huge amount of chemical, genomic and disease phe-
notype data is rapidly accumulated, but the drug-diseases
associations are still not clear. For this purpose, we design
a method of inferring drug- protein/gene-disease pheno-
type relationships with a network propagation model,
where genes with similar functional modules are related to
not only drugs but also the disease phenotype.
Methods
We demonstrate the integrated network including three
heterogeneous networks of the phenotype, drug, protein
homo-networks and two hetero-networks capture interac-
tions between two different homo-networks in Figure 1.
The homo-network is defined as an undirected graph
Gi = (Vi, Ei) where Vi is the node set and Ei is the edge set
in the homo-network i. Connections between two kinds of
homo-networks define as hetero-network, where the
nodes from different homo-networks are related to each
other. The hetero-network is defined as bipartite graph
Gij = (Vi∪Vj, Eij). Here, Eij represents the set of edges
which connect the nodes in different kinds of the homo-
networks i and j.
Construct phenotype homo-network
A node in a phenotype homo-network as a disease pheno-
type is extracted from Online Mendelian Inheritance
in Man (OMIM) database [18]. We use a scoring schema
of phenotypic similarities as edges that quantitatively
measures the phenotypic overlap of OMIM records con-
structed by van Driel [19] using text mining techniques.
If the similarity score of two diseases falls in the range
[0.6, 1], it means informative similarity which indicates
potentially relevant phenotypic similarity. On the other
hand, if the similarity score falls within [0, 0.3], it indicates
non-informative similarity. Therefore, we apply a logistic
function from [20] to convert the phenotypic similarity
scores among diseases into a value as close to 1 as possible
while the non-informative score into a value as close
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to 0 possible over all the entries in the phenotype similar-
ity score matrix. The symmetric similarity matrix Wp(pi,pj)
in phenotype homo-network denotes the phenotypic simi-
larity score between phenotypes pi and pj.
Construct drug homo-network using chemical similarity
We extract the FDA-approved drugs and their canonical
simplified molecular input line entry specification
(SMILES) from DrugBank database [21][22]. We calculate
the hashed fingerprints using Chemical Development
Kit (CDK) [23]. The chemical similarities are calculated by
two hashed fingerprints using Tanimoto coefficient [24].
It calculates the size of the common substructures over
the union between two fingerprints of the drugs which is
defined as sim(x, x’)=|x∩x’|/|x∪x’| between two chemical
structures of drug x and x’. The symmetric chemical struc-
tures similarity matrix as the edge weight in drug homo-
network is denoted as Wd and each value falls in the range
between zero (no bits in common) to unity (all bits the
same)
Construct protein interaction homo-network using gene
expression data
Protein-protein interactions provided an opportunity on
the discovery of relationships among proteins in the
mechanism of the drugs and human disease phenotype.
However, the PIN has its disadvantages: first, the informa-
tion in current PIN databases is partly complementary and
the combination of the multiple databases could improve
the knowledge of the protein interactions [25]. Second,
PIN in those databases only provides the functional
relations among the products of the genes and do not
provide information about the conditions under which the
interactions occur. Genome-wide expression profile can
help us to extract the changes of the genes which are
involved in the activity of a given disease or drug com-
pound by comparing multiple case-control data sets. The
co-expressed genes can reveal specific linkages which are
more likely to function together, and we apply Pearson
correlation coefficient for every pair-wise relation among
genes. The positive correlation indicates an increasing
linear relationship and negative correlation indicates
a decreasing linear relationship. On the other hand, the
correlation approaches to zero shows there would be little
or no association. By visualizing gene expression over-
expressed and down-expressed functional modules, we
take the absolute value of correlation value to capture
inhibitory activity (negative correlation) as well as activa-
tion activity (positive correlation). We define the weight
function as the product of the absolute value of correlation
and the sum of the absolute value of differential expression
changes between two corresponding genes in control and
case samples. The symmetric weighted matrix between all
interactions among all gene pairs is denoted as Wg and the














where Wg(gi,gj) denotes the weight function from gene gi
to gene gj.
∣∣∣Rdgigj
∣∣∣ denotes the absolute value of Pearson
Figure 1 The idea of our proposed method.
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correlation coefficient of the interaction between gene gi




gi are the average gene
expression values of gene gi in case sample and control
sample.
Integrated disease, protein interactions and chemical
homo-networks
The gene-phenotype hetero-network shows the relation-
ships between disease phenotype and disease-associated
genes extracted from OMIM database [18]. The drug-
protein hetero-network denotes the drug and its targets
which is obtained from DrugBank database [21]. The
asymmetric matrices Wpg, Wdg represent the adjacency
matrices of link structures from phenotype-gene relation-
ships and drug-target protein interactions, respectively.
If drug di has a target gj, then Wdg(di, gj) = 1, otherwise
Wdg(di, gj) = 0. When a drug target or disease-associated
gene has no link with other proteins in PIN, we set the
probability of connection to any other protein as 1/(n-1),
where n is the total number of proteins in PIN. Since n is
usually very large, so the probability will be very small.
The reason that we use small probability instead of zero
probability is to prevent a node in the network becoming
a “sink node” in PIN and allows the probability to be
propagated through the node.
Network propagation in the integrated network
We identify the inferring drug-disease associations
problem as probability propagation over a network
which simulates a random walker stochastically move
on query phenotype to its immediate neighbors in het-
erogeneous network [26,27]. We adopt the idea from
[28] which developed a label propagation algorithm for
an integrated network.
In order to balancing the influence on the nodes which
they are connected in the network, we normalize all simi-
larity matrices W to be a transition matrix S by a diagonal
matrix Dr(i,i) which indicates the sum of row i while
another diagonal matrix Dc(j,j) indicates the sum of column
j in the similarity matrix, respectively. If the similarity
matrix of a homo-network is symmetric, the diagonal















where i denotes the node in a homo-network and j
denotes the node in the other homo-network.
Given transition matrix S, diffusion parameter a and the
vector p0 with the initial probability distribution over
nodes, the probability transition process in network
propagation method on single network within t steps is
defined as:
pt = (1 − α) p0 + αSpt−1
The first term denotes the random walker can “restarts”
to the initial probability distribution among the nodes
with the diffusion parameter 1-a. The second term
denotes an iterative walk to reach the further nodes in the
network based on the transition matrix S and a diffusion
parameter a. The random walker will be trapped at initial
nodes if a is zero. Let Pt be a probability distribution
where a node in the network holds the probability of
finding itself in the iterative random walker process up to
the step t. After certain steps, the probabilities will reach
a steady state which the difference between Pt and Pt-1
measured by L2 norm falls below a very small value such
as 10-9.
We extend the network propagation on a single network
to our integrated network. The nodes receive the probabil-
ities from other nodes in the same homo-network, and
also can get the probabilities from nodes in other homo-
networks through hetero-networks [29]. Therefore, the
initial probability would be replaced by adding the addi-
tional information from its immediate neighbors through
hetero-networks [30]. The new initial probability vector
pi
0 in each homogeneous network i is proposed by









Where ai and bij denote the weights in homo-network i
and those between two homo-networks i and j, respec-
tively. Sij denotes the normalized transition matrix of the
hetero-network. Then, we should keep the probability of
the node be equal to one and we must further ensure the





If homo-network i connect to other k homo-networks,
we adopt the weight of bij the same as diffusion parameter
ai to the immediate neighbors in the other homo-
networks. We calculate ai + kai = 1 and obtain the weight
ai = 1 - kai. Finally, we further elaborate the network
propagation method on a homo-network i into:
pti = (1 − αi)
⎡











Thus, network propagation is calculated with an
enriched initialization from the other homo-networks
through hetero-subnetworks and the proof of convergence
is in [31].
Given a query phenotype, we first set the initial prob-
ability distribution over nodes where the probabilities to
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the query disease nodes set to one and other nodes in the
other homo-networks to zero. Second, we apply our net-
work propagation method iteratively until the probability
converges on each homo-network. Finally, we use the
coverged probabilities of the nodes in homo-networks as
initail probability distribution and then repeated the
network propagation processes until all homo-networks
converge to a final probability distribution.
Evaluation of association specificity between drug and
disease
In our method, we apply chemical similarity, gene expres-
sion, and phenotype similarity data and the transition in
the network propagation processes may skew the visitation
frequencies towards those supplied data values. Since the
frequencies of node visitations may also be highly biased
by the linkages in the network topology, the probabilities
of the nodes may directly reflect the relative centralities in
the network based on the local network connectivity [32].
In order to control the topological biases in PIN, we calcu-
late the reference visitation frequencies without taking the
gene expression profile of the specific disease phenotype
into consideration. Therefore, we set all the edge weights
among genes to one in PIN and get the reference probabil-
ities distribution Pi
ref over nodes in each homo-network i
using our method. Then, we evaluate the specificity of the
probability of a node using Z-score as the final normalized
score distribution which reflects the relevance nodes
related to the query phenotype.
Zi(v) =





Here, Pi(v) denote the probability of node v in homo-
network i using genomic data calculated by our method.
The functions avg and std denote the average and stan-





We adopt microarray data taken from [33] that consists
of 62 primary prostate tumors and 41 normal tissues
from Stanford Microarray Database (SMD) [34]. We use
genome-wide gene expression profiles from tissue samples
of 18 healthy normal controls and 27 patients with color-
ectal cancer evaluated by HG-U133 Plus 2.0 platform
microarrays (Affymetrix, Santa Clara) through from Gene
Expression Omnibus (GEO) database (GSE4183 and
GSE4107) [35,36].
Protein interaction network
We successfully obtained 137,037 interactions among
13,388 genes by integrating five protein interaction
network databases (HPRD, BIND, IntAct, MINT, and
OPHID) and by mapping the UniProt protein ID to the
human Entrez gene ID, erase the duplicated interaction
pairs.
Phenotype network and Phenotype-genotype
hetero-network
The OMIM database constructed the catalogue of genetic
diseases in human and provides the phenotype-genotype
association for 14,433 genes and 5,080 diseases [18].
The gene-phenotype hetero-network contains 275 disease
phenotypes and 649 genes from 877 relations while
mapping the genes in microarray data and PIN.
Drug network and drug-target hetero-network
We collect 1,571 FDA-approved drugs and 1,410 of them
with available SMILES data in DrugBank database [21].
There are 4,456 relations between 1,215 drugs and 1,141
targets to be the drug-target hetero-network.
Benchmark of drug-disease associations
We extract 53 and 106 known associations between drug,
prostate cancer and colorectal cancer extracted from CTD
database [6] in May 2013 as our benchmark.
The performance of our method
We compare our method with the previous state-of-the-
art Cmap project to evaluate the performance [10].
We first prepare the ranked lists of over-expressed genes
and down-expressed genes in both prostate and colorectal
cancers which are conducted with affymetrix HG-U133A
platform for Cmap project. The number of over-expressed
and under-expressed gene signature in prostate cancer
and colorectal cancer microarray data with different fold
changes are shown in Table 1. Given the disease-specific
gene signature as input query, the drug compounds
ranked lists obtained from Cmap which are scored based
on how well they are correlated with the input query. The
score of 1 represents the input query perfect matches the
changes among drug expression profiles in the database,
Table 1 The number of gene signature with different fold changes in prostate cancer and colorectal cancer
Cancer Prostate cancer Colorectal cancer
Fold change 1.0 1.1 1.2 1.3 1.4 1.2 1.4 1.6 1.8 2
# over-expressed genes 89 60 45 31 27 539 308 175 106 68
# down-expressed genes 232 156 115 86 58 72 42 27 12 5
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-1 represents perfect anti-correlation between them, and
0 represents a null match. Both negative and positive
enrichment belong to the drug-disease associations.
Therefore, we take the absolute values of scores and
re-rank them and higher score represents the stronger
drug-disease associations. Due to Cmap project is derived
from the expression profile of a drug compound to the
isolated cell lines, multiple instances may correspond to
same drug and even with same dose in the obtained
results. We calculate the maximum score of multiple
instances that correspond to the same drug as the asso-
ciated score of a specific drug for dealing with such cases.
In prostate and colorectal cancer data, we use 601 drug
compounds which are overlapped between DrugBank and
Cmap results and the drug rank list have shown in the
previous works [37]. We compute observed the area under
the receiver operator characteristic (ROC) curve (AUC)
for analyzing the quality of performance in Figures 2
and 3, respectively. The Cmap method obtains much
lower AUC of 0.59 ± 0.04 and 0.59 ± 0.03 under the gene
signature with different fold changes while our method
obtains 0.94 and 0.89 in prostate cancer and colorectal
cancer respectively. Previous study showed that only
depending on the drug response expression profile is
incapable to acquire the drug-disease associations accu-
rately due to the profiles generated under different condi-
tions [38]. There are several problems that limit the
performance in Cmap project: First, the set of differentially
expressed genes that constitute disease signatures or drug
signatures were chosen empirically that cannot guarantee
the biological relevance of the selected signatures. A bad
selection of signatures may tend to capture similarities in
the experimental settings rather than revealing the under-
lying mechanisms. Second, only the overlap among genes
between disease state and drug treatments are not quanti-
fied as the overall effect of a drug and the values of differ-
ential expression are also not taken into account in Cmap
project. Therefore, the feasibility and benefits of using
network-based analyses of chemical, genomic and pheno-
type data provides a good chance to reveal drug-disease
associations.
The AUC with varying diffusion parameters
We investigate the systematic effect of the different diffu-
sion parameters among networks in our approach. We
apply the diffusion parameters ai ∈{0.1, 0.3, 0.5, 0.7, 0.9}
used in the experiments and 125 combinations of the
parameters are tested. The ranking performances of our
method with different combinations are measured
by AUC values in Figure 4. The results show that the
diffusion parameters set in drug, gene, and phenotype
homo-network ad, ag, and ap as 0.1, 0.7 and 0.3 can get
a higher AUC in both prostate and colorectal cancer.
A higher similarity score between the chemical structures
of a pair of drugs may sometimes have different targets to
affect different functional modules in PIN. The drugs with
similar chemical structures without binding to similar
enzymes would reduce the predictive accuracy for drug
Figure 2 ROC curve among Cmap and our method in prostate cancer.
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similarity [39]. On the other hand, the bit-comparison
method of chemical structures using Tanimoto coefficient
also has its limitations [40]: First, this kind of method does
not include biochemical information at the atomic level of
the representation. Second, sometimes it may yield low
similarity values and it has an inherent bias related to the
size of the molecules that are being sought. Furthermore,
many physiological effects cannot be predicted accurately
by chemical structure properties alone without more
detailed information of metabolic and pharmacokinetic
transformations of drugs [41]. Those may be the reason
that why the diffusion parameter value in the drug
network should be relatively smaller in our experiment.
PIN tends to have much higher diffusion parameters to
get higher AUC and it is reasonable to infer drug-disease
associations not only by targeting the specific proteins
Figure 3 ROC curve among Cmap and our method in colorectal cancer.
Figure 4 AUC comparison among the different combinations of the diffusion parameters in (a) prostate cancer and (b) colorectal cancer.
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directly but also by modulating the pathways involved in
the pathological process [42].
The performance of our method with different data source
The drug is designed to target on the primary targets, but
it also may interact with unexpected proteins (called off-
targets) to trigger the associated biological processes and
pathways. It may display undesired off-target toxicity or
drug reposition for the disease phenotype. Therefore, we
aim to add additional drug targets information to better
understanding of dynamic processes under drug exposure.
The database STITCH contains the relations between
chemicals as chemical-chemical associations (CCA), and
chemicals and their interacted proteins as drug-protein
interactions (DPI) which are all curated by the evidence
derived from experiments, publicly databases and
the literature extraction [43]. However, the textual co-
occurrence from text mining does not necessarily indicate
meaningful relationships [44]. Therefore, we take 29,275
chemical-chemical interactions and 45,567 chemical-
protein pairs from STITCH excluded the relations
extracted from the text mining method. In the rank lists of
1,410 drugs, our method with the chemical structures
similarity from CDK in drug homo-network and the
chemical-protein interactions from STITCH in drug-
protein hetero-network obtain highest AUC of 0.936
and 0.861 in prostate cancer and colorectal cancer dataset
in Figure 5 and 6, respectively. It shows that our method
with more potential off-targets from STITCH gets higher
AUC than that with only primary drug targets from
DrugBank in both prostate cancer and colorectal cancer
data. Due to only a limited number of chemical-chemical
associations have been identified in STITCH [45], its
performance is worse than the associations constructed by
chemical structures similarity from CDK in drug homo-
network.
Case study: prostate cancer
Potential drug and prostate cancer relations
We run our method with diffusion parameters ad, ag, and
ap as 0.1, 0.7 and 0.3 in drug, gene/protein, and phenotype
homo-networks and display 26 drug-prostate cancer asso-
ciations by evaluating the one-tailed test at 0.01 level of
significance with Z-score > 2.33 in Table 2. Since the
predictions are not regarded as true and we need to be
further validated using external literature support,
17 known associations are approved by the benchmark
and other 7 associations are supported by the literature.
The man with geriatric cancer may have prostate enlarge-
ment or prostate cancer at a higher risk while taking fluox-
ymesterone. On the other hand, if people has known or
suspected prostate cancer, oxandrolone and drostanolone
related to androgen receptors are not recommended to be
taken in certain medical conditions. Previous clinical
studies showed that prostate-specific antigen (PSA) plays
an important tumor marker for prostate cancer in male
and nandrolone phenpropionate is an androgen receptor
agonist and previous study showed that it can decrease
Figure 5 ROC curve of our method with different data source supported in prostate cancer.
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cell growth of prostate cancer LNCaP cells [46]. The
primary action of cyproterone is to suppress the activity of
the androgen hormones via competitive antagonism of
the androgen receptor and inhibition of enzymes in the
androgen biosynthesis pathway [47]. While the patients
with metastatic prostate cancer were given mitomycin,
the clinical results show good anti-tumour activity in
metastatic prostate cancer and low toxicity in a phase II
chemotherapy study [48]. Due to the androgens can
stimulate the growth of prostate cancer cells, previous
phase II trial study in 2012 demonstrated the hormone
therapy using exemestane with or without bicalutamide
may fight prostate cancer [49].
The significant functional modules related to the
drug-prostate cancer association
There are 31 genes with Z-score > 2.33 which are strongly
related to 18 drugs and prostate cancer associations. We
use the functional annotation analysis to investigate the
functional enrichment of them via GSEA toolkits [50]. We
select 4 annotation categories related to the functional
pathways and processes including Biological Process
(BP) in Gene Ontology (GO), KEGG, BIOCARTA, and
Figure 6 ROC curve of our method with different data source supported in colorectal cancer.
Table 2 Drug-prostate cancer associations
Drug ID Drug Name Score Drug ID Drug Name Score
DB01420a Testosterone Propionate 13.69 DB01216a Finasteride 4.85
DB00621b Oxandrolone 12.76 DB00367a Levonorgestrel 4.46
DB00984b Nandrolone phenpropionate 9.69 DB00262a Carmustine 4.16
DB00858b Drostanolone 8.14 DB06710a Methyltestosterone 4.00
DB04839b Cyproterone 7.78 DB00227a Lovastatin 3.90
DB00687a Fludrocortisone 7.44 DB00783a Estradiol 3.77
DB00665a Nilutamide 6.56 DB01599 Probucol 3.77
DB01185b Fluoxymesterone 6.31 DB00279 Liothyronine 3.22
DB01128a Bicalutamide 6.20 DB00421a Spironolactone 3.01
DB01395a Drospirenone 6.17 DB01406a Danazol 2.99
DB00305b Mitomycin 5.24 DB00624a Testosterone 2.96
DB00499a Flutamide 5.07 DB00396a Progesterone 2.77
DB00990b Exemestane 5.03 DB00928a Azacitidine 2.61
a. Primary therapeutic function approved by our benchmark; b. supported by literature
Huang et al. BMC Medical Genomics 2013, 6(Suppl 3):S4
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REACTOME pathways to do the functional enrichment.
The enriched functional biological processes and pathways
of those genes with p-value < 0.05 are shown in Table 3
and the detailed information is obtained from GSEA and
DAVID gene functional classification tool [51] see Addi-
tional file 1. The most significantly enriched terms of the
regulation of apoptosis, cell cycle, p53 signaling and DNA
repair indicate that those genes serve important roles
in drug and prostate cancer association. The BRCA2
mutation contributing to the young-onset prostate cancer
has shown to be related to the Fanconi anemia pathway
and DNA repair processes [52,53]. The prostate apoptosis
response (Par) factor-related proapoptotic function is asso-
ciated with prostate tumor progression and sheds light
on the effects of the AR pathway on cell survival and
apoptosis [54]. Interestingly, this functional module may
be also for programmed cell death in response to
induce apoptosis in neurodegenerative disorders such as
Alzheimer’s and Huntington’s disease pathway [55].
With literature support, Par-4 has also been initially
characterized in prostate cancer and also linked with
the direct induction of apoptosis and even recognized to
be a new target in pancreatic cancer [56].
Case study: colorectal cancer
Potential drug and colorectal cancer relations
We display 37 significant drug-colorectal cancer associa-
tions with Z-score > 2.33 in Table 4. There are 28 known
associations between drugs and colorectal cancer approved
by our benchmark and 4 associations with literature
support. Pyridoxal phosphate (PLP) is an important cofac-
tor in the reactions of amino acid metabolism and
previous studies indicated that increased blood PLP levels
are associated with a reduced risk of colorectal cancer [57].
The previous findings showed the association between
dietary fats and colorectal cancer, and a significant inverse
association was found between colorectal cancer and
alpha-linoleic acid [58]. The results of this study suggest
that substituting alpha-linoleic acid in the diet may reduce
the risk of the colorectal cancer [58]. Previous works
examined the effect of arsenic trioxide (As2O3) at various
concentrations on the cell growth of the colon cancer cell
lines and showed that the growth of all cell lines was
gradually suppressed with As2O3 in comparison with that
obtained without treatment [59,60]. Polyamines, organic
compounds having two or more amino groups, have been
shown to play an important role in the growth and survival
in colorectal cancer [61]. We also find that spermine,
a polyamine, may be a candidate target for therapeutic
intervention in colorectal cancer [62]. The activity of the
polyamine-synthesising enzyme, ornithine decarboxylase
(ODC), is very highly expressed in proliferative HT-29
colon cancer cells comparing to those from control
samples, as well as in our case study [63]. L-ornithine is
apparently efficiently utilized in the ODC pathway and
is also considered as growth factors involved in cell proli-
feration and differentiation regulated by amino acids meta-
bolism [64]. The growing studies indicated the potential
effectiveness of bortezomib in treatment of patients with
HCT116 colon cancer by significantly increasing survivin
expression [65,66]. The increasing evidences determined
that the relationships among certain bacteria and cancer
exist but the detail mechanism still unclear [67]. In our
results, we interestingly find that an antibiotic drug zana-
mivir for bacterial infection may cause or cure colorectal
cancer [68].
The significant functional modules related to the drug-
colorectal cancer association
The enriched functional biological processes of 44
significant genes in drug-colorectal cancer associations by
investigating the functional enrichment are shown in
Table 5 and the detailed information see Additional file 2.
The popular enriched functional terms of the gene mod-
ules are regulation of Glycogen synthase kinase 3 (GSK-3)
pathway, innate immune system, Wnt signalling pathway
[69] and apoptosis pathway which all appear to be promis-
ing biological processes associated with colorectal cancer.
The activity of GSK3b expression in colorectal cancer
patients is higher than those in their normal samples and
the GSK3b inhibitor may induce apoptosis in human
colorectal cancer cells [70,71]. Lipopolysaccharide (LPS)
elicits several immediate proinflammatoy responses
including CD14, Toll-like receptors, phosphatidylinositol-
3’-kinase (PI3K)/Akt signaling, myeloid differentiation fac-
tor, nuclear factor kappa-light-chain-enhancer of activated
B cells (NF-kB) transcription factors, and also promotes
downstream b1 integrin function in tumor growth and
progression thereby increasing the adhesiveness and meta-
static capacity of colorectal cancer cells [72-74]. Here, we
present evidence that S100A8/A9 actives the downstream
genes associated with Mitogen-activated protein kinases
Table 3 Functional modules related to the drug-prostate
cancer associations
Database Functional modules p-value
REACTOME Fanconi anemia pathway 4.65E-5
KEGG Huntington’s disease pathway 1.60E-4
KEGG p53 signaling pathway 9.72E-4
BIOCARTA BRCA1, BRCA2 and ATR pathway 1.61E-3
GO, KEGG Cell cycle 1.81E-3
REACTOME DNA Repair 3.89E-3
GO Negative regulation of cell proliferation 9.75E-3
KEGG Alzheimer’s disease pathway 1.21E-2
GO Apoptosis 1.26E-2
KEGG Pancreatic cancer pathway 1.69E-2
KEGG Viral myocarditis 1.83E-2
REACTOME Electron transport 2.13E-2
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(MAPK) and NF-kB signaling pathways to promote tumor
growth and metastasis and the expression of S100A8/A9
on myeloid cells is also essential for development of colon
tumors in mice model [75]. Untersmayr detected Fc epsi-
lon RI (FcεRI)-positive epithelial cells in the colon cancer
patients [76]. There has been a growing importance of the
neurotrophin signalling in a variety of human cancers
including colorectal cancer and malignant gliomas in
particular [77]. Our study also denotes that the signifi-
cances of p53, hypoxia inducible factor-1 alpha pathway,
and vascular endothelial growth factor (VEGF) expression
in colorectal cancer [78].
Table 4 Drug-colorectal cancer associations
Drug ID Drug Name Score Drug ID Drug Name Score
DB0017a Adenosine triphosphate 12.35 DB00313a Valproic Acid 4.20
DB01593a Zinc 8.66 DB00162 Vitamin A 3.77
DB00591 Fluocinolone Acetonide 8.25 DB00131 Adenosine monophosphate 3.74
DB00163a Vitamin E 7.13 DB00129b L-Ornithine 3.72
DB01262a Decitabine 7.02 DB00947a Fulvestrant 3.46
DB00435a Nitric Oxide 6.70 DB00741a Hydrocortisone 3.34
DB00783a Estradiol 6.40 DB01064a Isoproterenol 3.21
DB00328a Indomethacin 6.35 DB01128a Bicalutamide 3.17
DB00755a Tretinoin 6.26 DB00773a Etoposide 3.15
DB00114b Pyridoxal Phosphate 5.91 DB00481a Raloxifene 3.10
DB00544a Fluorouracil 5.62 DB00305a Mitomycin 3.05
DB00132b Alpha-Linolenic Acid 5.61 DB00188b Bortezomib 2.77
DB00396a Progesterone 5.59 DB01005a Hydroxyurea 2.66
DB00997a Doxorubicin 5.52 DB00619a Imatinib 2.61
DB00179a Masoprocol 5.09 DB02546a Vorinostat 2.53
DB00558 Zanamivir 5.03 DB00928a Azacitidine 2.47
DB01169a Arsenic trioxide 4.38 DB00498a Phenindione 2.44
DB00127a Spermine 4.38 DB00548 Azelaic Acid 2.39
DB00834a Mifepristone 4.21
a. Primary therapeutic function approved by our benchmark; b. supported by literature
Table 5 Functional modules related to the drug-colorectal cancer associations
Database Functional modules p-value
BIOCARTA GSK3 pathway 7.29E-14
KEGG Endometrial cancer 2.30E-11
KEGG Colorectal cancer 4.32E-9
KEGG, BIOCARTA, REACTOME Toll like receptor pathway 5.79E-9
KEGG Prostate cancer 1.36E-6
BIOCARTA P53hypoxia pathway 1.93E-6
KEGG Lung cancer 2.30E-6
KEGG Glioma 5.82E-6
KEGG Renal cell carcinoma 8.40E-6
KEGG Melanoma 9.01E-6
KEGG Chronic myeloid leukemia 1.03E-5
KEGG VEGF signaling pathway 1.26E-5
KEGG Innate Immune System 1.29E-5
KEGG Fc epsilon RI signaling pathway 1.52E-5
REACTOME Regulation of ornithine decarboxylase (ODC) 4.28E-5
KEGG Pancreatic cancer 1.74E-4
KEGG Wnt signaling pathway 3.34E-4
GO Apoptosis 1.54E-3
KEGG Neurotrophin signaling pathway 1.62E-3
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Conclusions
We integrate the information of drug, genomic and
disease phenotype from available experimental data and
knowledge as weighted networks and their connected
relationships together. We apply disease-oriented net-
work propagation approach for inferring and evaluating
the likelihood of the probability between drugs and
query disease. In our experiment, we adopt the prostate
cancer and colorectal cancer as our case study and the
results clearly outperform previous Cmap project. Our
results are also found to be significantly enriched in
both the biomedical literature and clinical trials. The
success of our methods can be attributed as follows:
First, we integrate heterogeneous data and knowledge
about disease phenotype, chemical structure of drugs,
and gene expression into our model. Second, our
network propagation method combines the information
not only from the single network but also derived the
information from other connected homo-networks to
infer the drug-disease association. Finally, our method
with off-targets information gets higher performance
than that with only primary drug targets in both test
data. We believe that the combination of network and
heterogeneous data source could help us to generate
new hypotheses to infer the drug-disease associations
and even speed up the drug development processes.
Our study provides opportunities for future toxicoge-
nomics and drug discovery applications but the limita-
tion is the difficulty in distinguishing the positive and
negative associations between drug and disease. In the
future, we can choose different methods to calculate the
chemical structural similarity between drugs, which could
improve the limitations by using Tanimoto coefficient.
On the other hand, our approach heavily relies on the
weights for the edges in each network derived from the
existing knowledge of drugs, targets, protein, disease or
reported databases, or experimental results from the pub-
lic database and the incompleteness of such information
would limit our prediction power. We can also integrate
various data sources such as drug response profile,
side effect and pharmacological data and therapeutic/
toxicological expression profiles to verify the reliability
and confidence of the interactions.
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toolkit.
Additional file 2: The functional enrichment canonical pathways of
genes in colorectal cancer. We filter the functional enrichment
canonical pathways of the overlap of the significant genes related to the
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toolkit.
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